One donor, two transplants: could this end lifelong Anti-Rejection drugs?
NCT ID NCT01758042
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection drugs. Participants received a milder chemotherapy and radiation regimen to lower side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Combined bone marrow and kidney transplant from a partially matched related donor
What this could lead to
If successful, this approach could reduce the need for lifelong anti-rejection drugs after kidney transplant and treat both the blood disorder and kidney disease in one procedure.
What could go wrong
This is a very small pilot study with only 10 participants, so results may not apply broadly. The procedure carries serious risks including infection, graft-versus-host disease, and treatment-related death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States